Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of LHA510 in Elderly and AMD Patients
NCT02076919Phase 1Completed
- Sponsor
- Alcon Inc.
- Start
- Feb 2014
- Primary completion
- Jun 2014
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
01
Overview
Phase 1, randomised, double-blind trial of acrizanib in age-related macular degeneration (AMD) (4 arms), sponsored by Alcon Inc. Primary endpoints: Number of Subjects With a Serious Adverse Event Related to Study Drug and Number of Subjects Experiencing a Non-serious Adverse Event. Started Feb 2014; status: completed.
02
Drugs
acrizanib
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NCT02076919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02076919.